RWC-340B Responds to Energy and Commerce Draft Legislation on Drug Shortages
View or Share as PDF
RWC-340B Responds to Senate Bipartisan Request for Information on 340B
View or Download Statement PDF Contact: Adam Croglia acroglia@trysailstrategies.com FOR IMMEDIATE RELEASE RWC-340B Responds to Senate Bipartisan Request for Information on 340B WASHINGTON, DC – On July…
Ryan White Clinics for 340B Access Supports Proposed HIV Legislation – 7.19.23
View or Download PDF July 19, 2023 FOR IMMEDIATE RELEASE Contact: Peggy.Tighe@PowersLaw.com Ryan White Clinic Association Strongly Supports New Legislation Led by U.S. Senators Scott, Lujan, and Peters that…
Webinar Replay: Intersection of 340B and Medicaid
Click Here to View Key topics to be covered include: 1. Understanding the different ways in which the 340B and Medicaid programs intersect 2. Analyzing CMS’s recently-proposed Medicaid drug…
RWC-340B Responds to Drug Shortages RFI, Issued by Reps. Rodgers and Crapo
View PDF Here July 7, 2023 Chair McMorris Rodgers and Ranking Member Crapo: On behalf Ryan White Clinics for 340B Access (RWC-340B), we write in response to your inquiry…
Boehringer Ingelheim Broadens Contract Pharmacy Restrictions
Boehringer Ingelheim (BI) is among the 23 manufacturers that currently restrict contract pharmacy relationships with covered entities. It is also the 16th manufacturer to broaden its restrictions on contract pharmacies following the…
Updated Chart: Pharmaceutical Manufacturer 340B Price Restriction Policies and Exemptions Summary
View Here: Pharmaceutical Manufacturer 340B Price Restriction Policies and Exemptions Summary 6.21.23
National Ryan White Clinic Organization Fires Back at Gilead-Funded “Study” Riddled with Inaccuracies, Faulty Assumptions, and Profit-Centered Analysis
PRESS STATEMENT: FOR IMMEDIATE RELEASE June 20, 2023 National Ryan White Clinic Organization Fires Back at Gilead-Funded “Study” Riddled with Inaccuracies, Faulty Assumptions, and Profit-Centered Analysis The…
Novo Nordisk Tightens Restrictions on 340B Drugs Dispensed by Contract Pharmacies; Organon Becomes the 22nd Manufacturer to Issue Restrictions
Novo Nordisk Tightens Restrictions on 340B Drugs Dispensed by Contract Pharmacies; Organon Becomes the 22nd Manufacturer to Issue Restrictions On June 1, 2023, Novo Nordisk and Organon each announced restrictions…
Gilead Funds BRG Study Taking Aim at 340B Grantees
Gilead Funds BRG Study Taking Aim at 340B Grantees On May 22, 2023, the Berkeley Research Group (BRG) published a “study” titled “Federal Grantee Clinics and the 340B Drug…